SCHEMBL3909752

SCHEMBL3909752

CC(=O)N1CCC(C(=O)O)(c2ccc([N+](=O)[O-])cc2)CC1

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 1/20 0.55
HPGD P15428 1/20 0.55
KMT2A Q03164 7/20 0.45
TET3 O43151 4/20 0.45
FBXL19 Q6PCT2 4/20 0.45
CXXC5 Q7LFL8 4/20 0.45
KDM2B Q8NHM5 4/20 0.45
CXXC4 Q9H2H0 4/20 0.45
KDM2A Q9Y2K7 4/20 0.45
TET1 Q8NFU7 3/20 0.45
NPSR1 Q6W5P4 2/20 0.44
LMNA P02545 2/20 0.44
MAPT P10636 1/20 0.44
HTR1E P28566 1/20 0.44
S1PR3 Q99500 1/20 0.44
MEN1 O00255 3/20 0.44
CYP1A2 P05177 2/20 0.44
CYP2C19 P33261 2/20 0.44
CYP2C9 P11712 1/20 0.44
MAPK1 P28482 1/20 0.41

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL1769201 0.83 NPSR1 (0.50) ALDH1A1KMT2ANPSR1LMNAMAPT
SCHEMBL3900070 0.81 AKR1C1 (0.59) KMT2ANPSR1LMNAMAPTHTR1E
SCHEMBL3224174 0.81 NPSR1 (0.55) ALDH1A1KMT2ANPSR1LMNAMAPT
SCHEMBL12987813 0.80 KMT2A (0.49) ALDH1A1HPGDKMT2ATET3FBXL19
SCHEMBL3901907 0.78 ALDH1A1 (0.52) ALDH1A1HPGDLMNAMAPTMAPK1
SCHEMBL3904809 0.77 L3MBTL1 (0.64) ALDH1A1KMT2ANPSR1LMNAMAPT
SCHEMBL6607473 0.76 NPSR1 (0.52) ALDH1A1HPGDKMT2ANPSR1LMNA
SCHEMBL10549794 0.75 NPSR1 (0.46) ALDH1A1KMT2ANPSR1LMNAMAPT
SCHEMBL10349986 0.75 NPSR1 (0.46) ALDH1A1KMT2ANPSR1LMNAMAPT
SCHEMBL10512932 0.75 ALDH1A1 (0.48) ALDH1A1HPGDKMT2ALMNAMEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 19 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-9394289-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 US disclosed
US-9394289-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 US disclosed
US-9394289-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2016-07-19 US disclosed
EP-2016070-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-01-13 EP disclosed
EP-2016070-B1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2016-01-13 EP disclosed
CN-101472914-B C-FMS kinase inhibitors JANSSEN PHARMACEUTICA NV 2015-05-20 CN disclosed
US-20140378457-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-12-25 US disclosed
US-20140378457-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-12-25 US disclosed
US-20140378457-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA NV (BE) 2014-12-25 US disclosed
US-8859602-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-10-14 US disclosed
US-8859602-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-10-14 US disclosed
US-8859602-B2 Inhibitors of c-fms kinase JANSSEN PHARMACEUTICA NV (BE) 2014-10-14 US disclosed
CN-101472914-A C-FMS kinase inhibitors JANSSEN PHARMACEUTICA NV (BE) 2009-07-01 CN disclosed
EP-2016070-A1 INHIBITORS OF C-FMS KINASE Janssen Pharmaceutica, N.V. (BE) 2009-01-21 EP disclosed
WO-2007124319-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
WO-2007124319-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA N.V. (BE) 2007-11-01 WO disclosed
US-20070249680-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed
US-20070249680-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed
US-20070249680-A1 INHIBITORS OF C-FMS KINASE JANSSEN PHARMACEUTICA, N.V. (BE) 2007-10-25 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20140378457-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES ALDH1A1 4702/4885HPGD 4432/4885KMT2A 844/4885
US-20070249680-A1 INHIBITORS OF C-FMS KINASE MUSK, FRK, FES ALDH1A1 4702/4885HPGD 4432/4885KMT2A 844/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.